Reshape Lifesciences Stock Fundamentals
| RSLS Stock | USD 0.17 0.01 6.25% |
ReShape Lifesciences fundamentals help investors to digest information that contributes to ReShape Lifesciences' financial success or failures. It also enables traders to predict the movement of ReShape Stock. The fundamental analysis module provides a way to measure ReShape Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ReShape Lifesciences stock.
At this time, ReShape Lifesciences' Other Operating Expenses is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 24.6 M in 2024, whereas Operating Income is likely to drop (15.4 M) in 2024. ReShape | Select Account or Indicator |
ReShape Lifesciences Company Return On Equity Analysis
ReShape Lifesciences' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current ReShape Lifesciences Return On Equity | -2.21 |
Most of ReShape Lifesciences' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
ReShape Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, ReShape Lifesciences has a Return On Equity of -2.2059. This is 90.8% lower than that of the Health Care Equipment & Supplies sector and 74.73% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
ReShape Lifesciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ReShape Lifesciences's current stock value. Our valuation model uses many indicators to compare ReShape Lifesciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ReShape Lifesciences competition to find correlations between indicators driving ReShape Lifesciences's intrinsic value. More Info.ReShape Lifesciences is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, ReShape Lifesciences' Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value ReShape Lifesciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ReShape Lifesciences' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ReShape Lifesciences' earnings, one of the primary drivers of an investment's value.ReShape Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in return on equity category among related companies.
ReShape Fundamentals
| Return On Equity | -2.21 | ||||
| Return On Asset | -0.84 | ||||
| Profit Margin | (1.31) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | (192.87 K) | ||||
| Shares Outstanding | 23.46 M | ||||
| Shares Owned By Insiders | 11.16 % | ||||
| Shares Owned By Institutions | 1.96 % | ||||
| Number Of Shares Shorted | 729.32 K | ||||
| Price To Book | 0.58 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 8.68 M | ||||
| Gross Profit | 6.8 M | ||||
| EBITDA | (14.48 M) | ||||
| Net Income | (11.39 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (16.96 M) | ||||
| Short Ratio | 1.38 X | ||||
| Earnings Per Share | (1.91) X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 29 | ||||
| Beta | 1.3 | ||||
| Market Capitalization | 4 M | ||||
| Total Asset | 10.73 M | ||||
| Retained Earnings | (635.57 M) | ||||
| Working Capital | 6.52 M | ||||
| Net Asset | 10.73 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 639 K | 671 K | |
| Total Revenue | 8.7 M | 5.4 M | |
| Cost Of Revenue | 3.1 M | 2.2 M | |
| Stock Based Compensation To Revenue | 0.09 | 0.08 | |
| Sales General And Administrative To Revenue | 1.19 | 1.13 | |
| Research And Ddevelopement To Revenue | 0.27 | 0.25 | |
| Capex To Revenue | (0) | (0.01) | |
| Revenue Per Share | 1.46 | 1.38 | |
| Ebit Per Revenue | (1.69) | (1.77) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ReShape Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ReShape Lifesciences' short interest history, or implied volatility extrapolated from ReShape Lifesciences options trading.
Currently Active Assets on Macroaxis
When determining whether ReShape Lifesciences is a strong investment it is important to analyze ReShape Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ReShape Lifesciences' future performance. For an informed investment choice regarding ReShape Stock, refer to the following important reports:Check out ReShape Lifesciences Piotroski F Score and ReShape Lifesciences Altman Z Score analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 1.457 | Quarterly Revenue Growth (0.36) | Return On Assets (0.84) | Return On Equity (2.21) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.